Patient Access to Experimental Drugs and AIDS Clinical Trial Designs: Ethical Issues
Cambridge Quarterly of Healthcare Ethics. 1996 Summer; 5(3): 400-409.
In this paper we address the question of whether the patients' position is ethically acceptable. At least two different ethical problems need to be analyzed in this regard. One is of a paternalistic nature, and the other claims that noncompliance with trial protocols and/or access to experimental drugs amounts to a harm in other situations. We analyze the practical implications of such patient reasoning and behavior for the predictive value of results gathered in clinical research. We conclude that the arguments that patients with terminal illnesses can present in favor of their actions are persuasive. In the last part of the article we suggest that improvements are urgently needed in protocols of clinical trials that address patient concerns and survival interests. Such improvements are possible. A possible trial design will be described briefly. The necessary changes would result in more ethical trial protocols and a predicted overall higher percentage of patient compliance than we see today. Also the predictive value of AIDS research clinical trials would increase for future patient generations.
Aids; Autonomy; Clinical Trials; Control Groups; Clinical Research; Drugs; Ethics; Ethics Committees; Harm; Health; Human Experimentation; Investigational Drugs; Moral Obligations; Nature; Paternalism; Patient Compliance; Patients; Placebos; Public Health; Random Selection; Research; Research Design; Research Ethics; Research Ethics Committees; Research Subjects; Terminally Ill; Volunteers; Vulnerable Populations;
Showing items related by title, author, creator and subject.